These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36506890)

  • 1. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing
    Oliva A; Volpicelli L; Di Bari S; Curtolo A; Borrazzo C; Cogliati Dezza F; Cona A; Agrenzano S; Mularoni A; Trancassini M; Mengoni F; Stefani S; Raponi G; Venditti M
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac121. PubMed ID: 36506890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).
    Boattini M; Bianco G; Bastos P; Comini S; Corcione S; Almeida A; Costa C; De Rosa FG; Cavallo R
    Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):155-166. PubMed ID: 37985552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy.
    Boattini M; Bianco G; Charrier L; Comini S; Iannaccone M; Almeida A; Cavallo R; De Rosa FG; Costa C
    Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):431-439. PubMed ID: 36806056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.
    Karaiskos I; Daikos GL; Gkoufa A; Adamis G; Stefos A; Symbardi S; Chrysos G; Filiou E; Basoulis D; Mouloudi E; Galani L; Akinosoglou K; Arvaniti K; Masgala A; Petraki M; Papadimitriou E; Galani I; Poulakou G; Routsi C; Giamarellou H;
    J Antimicrob Chemother; 2021 Feb; 76(3):775-783. PubMed ID: 33249436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
    Oliva A; Campogiani L; Savelloni G; Vitale P; Lodi A; Sacco F; Imeneo A; Volpicelli L; Polani R; Raponi G; Sarmati L; Venditti M
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad327. PubMed ID: 37476077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
    Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
    Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F; De Robertis A; Carone G; Dalfino L; Stufano M; Del Prete R; Mosca A
    New Microbiol; 2020 Jul; 43(3):136-138. PubMed ID: 32596740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in
    Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
    JAC Antimicrob Resist; 2023 Oct; 5(5):dlad113. PubMed ID: 37901589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 18. Ten Years of KPC-Kp Bloodstream Infections Experience: Impact of Early Appropriate Empirical Therapy on Mortality.
    Corcione S; De Benedetto I; Shbaklo N; Ranzani F; Mornese Pinna S; Castiglione A; Scabini S; Bianco G; Cavallo R; Mirabella S; Romagnoli R; De Rosa FG
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
    Kang Y; Zhou Q; Cui J
    J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.